Company
Incyclix Bio
| Industry | cell cycle control company developing INX-315, a CDK2 inhibitor for the treatment of advanced and resistant cancer |
|---|
Funding raised
| Company | Round | Date |
|---|---|---|
| Incyclix Bio | Series B Extension | 2025-08-25 |
Company
| Industry | cell cycle control company developing INX-315, a CDK2 inhibitor for the treatment of advanced and resistant cancer |
|---|
| Company | Round | Date |
|---|---|---|
| Incyclix Bio | Series B Extension | 2025-08-25 |